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Abstract
BACKGROUND: Over 500 viruses and bacteria primarily cause respiratory infections. During COVID-19 pandemic, 
these respiratory infections remain; i.e., COVID-19 has no ability to suppress these infections from the circulation. 
Therefore, it is very important to differentiate respiratory infections from COVID-19. Proving the presence of COVID-
19 with polymerase chain reaction (PCR) is not evidence that the disease was caused by this virus. Possible 
options are: First, a random encounter of the virus in the patient’s upper respiratory tract; second, further possible 
colonization with a coronavirus (or with COVID-19); the third option is to have an infection; and the fourth possibility 
is to have a disease or COVID-19 upper respiratory infection. Unfortunately, the method with PCR, although it is 
with high sensitivity and specificity, does not help us to distinguish which of these four possibilities are in question.
AIM: We aimed to present a guide to leading a patient with symptoms of an acute respiratory infection during a 
coronavirus pandemic (COVID-19).
RESULTS: A pandemic of COVID-19 shows that many patients get primary viral pneumonia, but people with normal 
immune system have no problem recovering. People with reduced immunity die from COVID-19, as opposed to the 
pandemic influenza virus. It is indirectly concluded that COVID-19 in itself is not very virulent, but it weakens the 
immunity of those infected who already have some condition and impaired immunity. The available scientific papers 
show that there is no strong cytokine response, patients have leukopenia and lymphopenia, some patients have 
a decrease in CD4 T-lymphocytes. From the results of the autopsies available so far, it is clear that there are very 
few inflammatory cells in the lungs and a lot of fluid domination. Hence, SARS-Cov-2 only somehow speeds up the 
decline in immunity. The previously published radiographic findings of COVID-19 patients, gave a characteristic 
findings of the presence of multifocal nodules, described as milky glass, very often localized in the periphery of the 
lung. Whether it is typical pneumonia, atypical, viral, mixed-type pneumonia, or mycotic pneumonia, it can progress 
to severe pneumonia. The pneumonia becomes severe when breathing is over 30/min; diastolic pressure below 
60 mmHg; low partial oxygen pressure in the blood (PaO2/FiO2 <250 mmHg) (1 mmHg = 0.133 kPa); massive 
pneumonia, bilateral or multilayered lung X-ray; desorientation; leukopenia; and increased urea.
CONCLUSION: Patients with COVID-19 placed in intensive care units should be led by a team of anesthesiologists 
with an infectious disease specialist or an anesthesiologist with a pulmonologist. Critical respiratory parameters 
should be peripheral oxygen saturation <90%, PaO2/FiO2 ratio 100 or <100, tachycardia above 110/min.
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Introduction
Acute respiratory infections are the most 
common infections in humans. As many as, two-thirds 
of all infections are thought to be respiratory infections. 
Over 500 viruses and bacteria primarily cause 
respiratory infections. Adults have a respiratory 
infection 3–5 times a year. At children, that number 
is much higher. Upper respiratory infections (rhinitis, 
sinusitis, tonsillopharyngitis, angina, gingivostomatitis, 
and laryngitis) are much more common than lower 
respiratory (tracheitis, bronchitis, bronchiolitis, alveolitis, 
and pneumonia). During COVID-19 pandemic, these 
respiratory infections remain, i.e., SARS-Cov-2 has no 
ability to suppress these infections from the circulation. 
Therefore, it is very important to differentiate respiratory 
infections from COVID-19. A good demarcation will 
increase the effectiveness of treating respiratory 
infections. We are very successful in treating bacterial 
infections. There are good antiviral drugs for the flu 
or influenza virus. We must consider about mycotic 
respiratory infections, and there are effective antifungal 
drugs for them.
Laboratory biochemical analyzes give us great 
help in distinguishing viral from bacterial infection and 
acting correctly in the decision to give an antibiotic. Thus, 
high sedimentation, leukocytosis with neutrophilia, high 
C-reactive protein (CRP), and elevated procalcitonin 
values are in addition to bacterial infection. Normal 
erythrocyte sedimentation rate, peripheral lymphocyte 
dominance (blood count), and normal CRP are in 
addition to viral infection.
Acute rhinitis (cold) – upper respiratory 
infection that from the 1st day goes with catarrhal 
symptoms (runny nose, sneezing, burning eyes, and 
tearing) with signs of general infectious syndrome and 
temperature up to 37.5°C to be treated as a common 
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cold syndrome (acute rhinitis). The most common 
causes are rhinoviruses, coronaviruses, influenza type 
C, parainfluenza, and respiratory syncytial virus (RSV).
Flu – if the patient had a high fever for 2–3 days 
(37.5–39.5), severe infectious syndrome (headaches, 
myalgias, arthralgias, bone pain, malaise, and 
drowsiness), there are no catarrhal signs, and the same 
occur after 2–3 days, then these patients have the flu and 
need to seek serological confirmation of influenza virus.
Catarrhus febrilis respiratorius – if the patient has 
a high fever from the 1st day, accompanied by symptoms 
of the general infectious syndrome, but from the 1st day, 
there are catarrhal symptoms (sneezing, runny nose, 
burning in the eyes, and tearing), then it is a so-called 
catarrhal febrile respiratory syndrome. This syndrome is 
most commonly caused by so-called atypical (intracellular) 
bacteria, primarily Mycoplasma pneumoniae, Legionella 
pneumophila, Chlamydia pneumoniae, and adenoviruses 
from viruses with this clinical picture [1], [2], [3].
Laboratory biochemical analysis will be very 
helpful in differentiating whether it is a bacterial or a 
viral infection. Thus, leukocytosis, with a predominance 
of polymorphonuclear in the peripheral smear, together 
with high CRP values (above 100 mg/L) and accelerated 
erythrocyte sedimentation rate (above 20 mm/1 h) goes 
in favor of bacterial upper respiratory infection and 
those patients regardless. The obtained microbiological 
and serological results should be treated with antibiotics 
and corona infections should be separated. Moderately 
elevated or normal values of leukocytes, elevated CRP 
but with values below 50 mg/l, moderately elevated 
erythrocyte sedimentation rate (10–20 mm/1 h), and 
clinical picture of catarrhus febrilis respiratorius (1st 
day temperature and catarrhal signs) atypical bacterial 
infection (M. pneumoniae, so-called Pontiac fever caused 
by L. pneumophila and C. pneumoniae) and should be 
treated with macrolide antibiotics or tetracyclines. If 
we have a predominance of lymphocytes (regardless 
of the values of leukocytes), the sedimentation of 
erythrocytes in normal values 5–10 mm/1 h, and CRP 
is with normal values of 1–10 mg/l or slightly elevated; 
then, it is a viral upper respiratory infection, called 
rhinitis syndrome. Possible causes are rhinoviruses, 
influenza type C, parainfluenza, and coronaviruses in 
adults, and in children, the most common causes are 
RSV, rhinoviruses, influenza type C, parainfluenza, and 
coronaviruses. If the epidemiological situation in the 
region goes with the confirmation of many cases with 
the confirmed presence of COVID-19, then the most 
likely upper respiratory infection is with a coronavirus. 
Proving the presence of SARS-Cov-2 with polymerase 
chain reaction (PCR) is not evidence that the disease 
was caused by this virus. Possible options are: First, 
a random encounter of the virus in the patient’s upper 
respiratory tract; second, possible colonization with a 
coronavirus (or with COVID-19); the third option is to 
have an infection; and the fourth possibility is to have 
a disease or COVID-19 upper respiratory infection. 
Unfortunately, the method with PCR, although it is 
with high sensitivity and specificity, does not help us 
to distinguish which of these four possibilities are in 
question. The infection does not cause any clinical 
problems, but can be proven by serological tests. Proof 
of the presence of IgM antibodies to SARS-Cov-2 by 
serological test is reliable and acceptable evidence that 
it is an upper respiratory infection caused by COVID-19. 
Regardless of the etiological cause of rhinitis, or even an 
upper respiratory infection is with COVID-19, treatment 
should be symptomatic, i.e., the patient should rest, use 
more fluids through the mouth (teas, juices), Vitamin 
C (in high doses), and nothing else. Antibiotics and 
corticosteroids are contraindicated, and analgesics, 
antipyretics, immunoglobulins, immunomodulators, 
etc., may cause harm. Patients with upper respiratory 
tract infection with COVID-19 should be treated at 
home [1], [3], [4], [5], [6], [7], [8].
From the epidemiological data so far, about 
15% of all COVID-19 patients develop lower respiratory 
tract infections. These primary viral pneumonias should 
be treated in a hospital. To increase treatment efficacy, 
and to reduce mortality, it is necessary to properly 
differentiate primary viral pneumonia with COVID-19 
from other pneumonia. Pneumonia is a serious disease 
with high mortality. They are the 10th leading cause of 
death in the world, and in the age group of 65, they 
are the sixth leading cause of death. There are several 
divisions of pneumonia, but the most appropriate 
is the division of hospital-acquired pneumonia and 
community-acquired pneumonia.
Hospital-acquired pneumonias are common 
conditions, especially in patients who have been placed 
on a respirator or have had a diagnostic procedure on 
the respiratory tract (bronchoscopy and biopsy). Of all 
intrahospital infections, 13%–18% have nosocomial 
pneumonia. These pneumonias are sent with a high 
mortality rate of 33%–50% depending on the cause: 
Streptococcus pneumoniae, Staphylococcus aureus, 
P. aeruginosa, Klebsiella, and Acinetobacter species.
Community-acquired pneumonia – The best 
results in practice are given by the division of typical 
and atypical pneumonia. Typical pneumonias have a 
rich auscultatory finding, the presence of small moist 
bronchial murmurs (crepitations), and/or impaired 
breathing in a particular region. This auscultatory 
finding is confirmed by a rich rentgenogram. Atypical 
auscultation pneumonia has a normal finding because 
the inflammation is in the interstitium and the airways 
are free. However, the X-ray has a rich finding and 
diagnoses pneumonia. Depending on the size of the 
lesion, both typical and atypical pneumonias may 
have small inflammatory foci (bronchopneumonia), 
segmental, lobular, or occupy multiple lobes, i.e., be 
multilobar/massive unilateral or bilateral pneumonia. 
The advantage of this division into typical and atypical 
is that this division helps for proper antibiotic treatment. 
Pneumonia mortality is reduced if appropriate 
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antibiotic treatment is started within the first 4–6 h. 
Typical pneumonia is most commonly caused by 
pneumococcus (S. pneumoniae), S. aureus, and 
Haemophilus influenzae. The good part is that all 
these causes are susceptible to the same groups of 
antibiotics. Our drug of choice is the third-generation 
cephalosporin for parenteral use, ceftriaxone in doses 
of 30–50 mg/kg/bw [1], [3], [8], [9], [10].
Atypical pneumonia is caused by viruses and 
so-called atypical intracellular causes (M. pneumoniae, 
L. pneumophila, Chlamydia pneumoniae, and Coxiella 
burnetii). The good side is that these intracellular 
bacteria are sensitive to macrolide antibiotics and 
tetracyclines. Unlike viral atypical pneumonia, we have 
a moderate increase in erythrocyte sedimentation rate 
of 15–30 mm/1h, and moderately elevated CRP, in 
addition to possible leukocytosis. The drug of choice 
during pandemic with COVID-19 should be azithromycin 
5 mg/kg/bw, preferably intravenously [1].
Another division of community-acquired 
pneumonia is primary and secondary. Primary pneumonia 
involves pneumonia caused by any infectious agent and 
is caused by a primary infection of the same cause. 
Secondary pneumonia is pneumonia caused by another 
upper respiratory infection, usually viral. This viral infection 
is thought to damage the respiratory epithelium, disrupting 
the defense mechanisms of the respiratory tract, and a 
secondary bacterial pneumonia develops within a few 
days to 2 months of the virus infection. These secondary 
bacterial pneumonias usually present with clinical and 
etiological presentation of typical pneumonia. Secondary 
pneumonia is also of fungal etiology (Cryptococcus 
neoformans, Pneumocystis jiroveci, Histoplasmosis, and 
Candida spp.). Fungal pneumonia occurs after a serious 
decline in immunity due to malignancy, severe chronic 
disease, starvation, treatment with cytostatics, and long-
term treatment with antibiotics. These pneumonias are 
much more common than we think and diagnose and are 
often the cause of death.
Primary pneumonia can be caused by any cause. 
Primary pneumonia is usually caused by a bacterium. 
Viruses rarely give rise to primary pneumonia. Primary 
viral pneumonia occurs when the virus is highly virulent. 
As a rule, primary viral pneumonia is difficult to treat and 
ends in death. Such primary viral pneumonias give many 
viruses (RSV, varicella, measles, and SARS-Cov-1). 
Influenza virus does not cause primary viral pneumonia 
during epidemics. However, during pandemics that 
occur after major, so-called shift antigenic changes, and 
when there is a population that will first encounter a new 
subtype of influenza virus, primary viral pneumonia is 
a common and significant cause of death. During the 
1918–1920 pandemic caused by the H1N1 subtype of 
Influenza A virus, such primary viral pneumonias were 
given only to people born after 1890, as most of the 
elderly had contact with the H1N1 subtype that had 
circulated before. Hence, young people with good and 
enhanced immunity died of primary viral pneumonia. 
The autopsy finding is up to 2 L of non-fibrinous fluid in 
the lungs. Coronaviruses typically present with a mild 
clinical picture of upper respiratory infection, followed 
by bacterial secondary pneumonia. No matter how and 
when the mutation occurred and COVID-19 occurred, it 
is evident that now in this COVID-19 pandemic, most of 
the deaths are due to the development of primary viral 
pneumonia and acute respiratory distress syndrome. 
During pandemics with influenza pneumonia with high 
mortality, young people have a good immune response, 
and the development of pneumonia is due to the 
virulence of the causative agent itself. A pandemic of 
COVID-19 shows that many patients get primary viral 
pneumonia, but people with normal immune system have 
no problem recovering. People with reduced immunity 
die from COVID-19, as opposed to the pandemic 
influenza virus. It is indirectly concluded that COVID-19 
in itself is not very virulent, but it weakens the immunity 
of those infected who already have some condition 
and impaired immunity. The available scientific papers 
show that there is no strong cytokine response, patients 
have leukopenia and lymphopenia, some patients have 
a decrease in CD4 T-lymphocytes. From the results of 
the autopsies available so far, it is clear that there are 
very few inflammatory cells in the lungs and a lot of fluid 
domination. Hence, COVID-19 only somehow speeds 
up the decline in immunity [1], [3], [8], [10], [11], [12].
It is necessary to strictly distinguish which 
patients have developed primary viral pneumonia 
from COVID-19, from patients who are positive for 
COVID-19, but for some other reason develop ARDS. 
These causes may be: The COVID-19 virus itself; other 
viruses; other infectious agents; holding patients on 
the respirator for more than 12 h; long-term oxygen 
delivery; hemodynamic disturbances; and alveolar 
capillary shunts, some internist notches [1], [3], [8].
X-ray Characteristics of Pneumonia
Lung X-rays certainly confirm the existence of 
a process in the lungs, but they rarely have specifics 
that will point us to the etiological cause. However, lobar 
pleuropneumonia suggests a possible pneumococcal 
etiology, cotton-like shadows (pneumatocele) of 
staphylococcal pneumonia, and a clearly limited round 
shadow of possible coxiellosis. The description of 
changes in the interstitium suggests that we have atypical 
bacterial pneumonia or interstitial viral pneumonia. The 
previously published radiographic findings of COVID-19 
patients, gave a characteristic findings of the presence 
of multifocal nodules, described as milky glass, very 
often localized in the periphery of the lung. It is this kind 
of finding of peripheral nodules such as milky glass that 
has been pathognomonic to Chinese radiologists who 
have only begun to diagnose primary viral pneumonia 
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with COVID-19 based on this finding. This finding in 
80–85% coincided with the positivity of SARS-Cov-2 
with PCR [9], [12], [13].
Specialist infectious disease specialists outside 
the pandemic successfully treat acute respiratory 
infections. However, during a pandemic due to a large 
number of patients, general practitioners and physicians 
with other specialties will be involved in the treatment 
of patients with COVID-19. A doctrinal approach in the 
treatment of patients with COVID-19 will give the best 
results, and there will be the smallest percentage of 
deaths.
Guide for the Treatment of Patients with 
Pneumonia
Pneumonia should be treated by an infectious 
disease specialist or pulmonologist. In conditions of 
increased number of pneumonias (larger than hospital 
capacities), the easier forms can be treated by a family 
doctor or internist.
Typical Pneumonia
If the pneumonia is characterized by typical 
pneumonia (rich auscultatory findings, radiographic 
confirmation, and laboratory biochemical analysis in 
addition to bacterial infection) to be treated doctrinally 
with third-generation cephalosporin for parenteral use, 
ceftriaxone 30–50 mg/kg/bw/i.v, once a day if up to 2 g, 
twice a day if given a maximum dose of 2 g ×2.0 g. 
The treatment should be in hospital. Mild forms can 
be treated on an outpatient basis. Intravenous fluids 
should be kept to a minimum. Do not include oxygen 
therapy. If the patient is treated on an outpatient basis, 
see the vital parameters at least once a day and follow 
the auscultatory findings. This therapy should be 
given a chance to work for at least 4 days. If there is 
a withdrawal of the auscultatory finding, a decrease 
in CRP values, a decrease erythrocyte sedimentation 
rate, regardless of the values of leukocytes in the blood, 
continue therapy for 10–12 days. After that control, lung 
graphics and a set of laboratory biochemical analyze. 
If after 4 days, there is a worsening of the pulmonary 
auscultatory finding, and/or a worsening of the condition, 
the patient should be treated exclusively in hospital. 
Replacing ceftriaxone with moxifloxacin 400 mg daily/iv 
(streptococcal pneumonia, the most common cause of 
typical pneumonia, is most sensitive to moxifloxacin, 
has a good effect on staphylococcal and anaerobic 
bacteria), and atypical intracellular bacteria. If there 
is a good assumption (a valid finding on lung X-ray, 
furunculosis…) that it is MRSA instead of moxifloxacin, 
immediately go with vancomycin 25–60 mg/kg/day. If 
it is assumed that aspiration and/or mixed pneumonia 
are possible, metronidazole 30 mg/kg/day should be 
added in two daily doses (clindamycin is a good choice 
10–30 mg/kg/day/i.m. or i.v. in two doses). Continue 
intravenous fluid delivery to a minimum. Oxygen should 
not be given as support. Avoid expectorants. Give 
antitussives if there is a persistent irritating cough. 
Moxifloxacin should be given a chance to be effective 
again for at least 4 days. If there is no withdrawal of the 
finding or the patient’s condition worsens, after 4 days of 
moxifloxacin therapy, replace with vancomycin [1], [14].
Atypical Bacterial Pneumonia
Atypical bacterial pneumonia can go into 
epidemic forms (M. pneumoniae, C. pneumoniae, and 
L. pneumophila) and can be easily transmitted from 
person to person. Due to the similar clinical picture and 
uncharacteristic laboratory biochemical parameters, 
they make serious differential diagnostic difficulties, i.e., 
we can hardly distinguish them from atypical pneumonia 
of viral origin. The drug of choice for atypical bacterial 
pneumonia (during COVID-19 pandemic) should be 
azithromycin 5 mg/kg/bw preferably intravenously. 
Treatment with other macrolide antibiotics or 
tetracyclines may not work because of the resistance 
of the primarily L. pneumophila to them. Treating these 
bacterial atypical pneumonias with cephalosporins or 
other beta-lactam antibiotics is without effect [1], [14].
Primary Viral Pneumonia
Many viruses can cause primary viral 
pneumonia, but the most common are influenza A virus, 
influenza B virus, RSV, human metapneumovirus, and 
adenovirus types 4 and 7. Influenza A viruses are 
statistically the most common primary pneumonia virus, 
but this occurs when there is a large shift antigenic 
change in hemagglutinin and neuraminidase and the 
appearance of a new circulatory subtype (H2N2). Some 
variants of circulating influenza subtype H1N1 know 
how to obtain many virulent features and give primary 
viral pneumonia. Because the epidemiological situation 
in the world regarding influenza A virus is calm (there 
is no new subtype, the variants that are now circulating 
are not so virulent), in a pandemic with COVID-19, it is 
expected that most of the primary viral pneumonia will 
be caused by COVID-19. Leukopenia, a weak immune 
response, a decrease in CD4 T-lymphocytes in some 
patients, and a characteristic radiographic finding of 
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peripheral nodules and/or changes described as an 
opaque glass suggest primary viral pneumonia with 
COVID-19 [8], [10], [11], [13], [15], [16], [17].
Recommendations for Therapy
Do not do more than possible. It should be 
borne in mind that in many papers in these patients 
were given various antiviral drugs, although it is known 
that they do not act on the virus. Even if there is a 
presumption that viral pneumonia may be caused by 
influenza viruses, it is not justified to give oseltamivir 
which is effective only if therapy is started within the 
first 36 h of illness (pneumonia occurs secondary after 
8 days). Antiretroviral drugs do not work either. Giving 
such antiviral drugs is only an alibi without scientifically 
proven support. Giving corticosteroids to most 
patients (according to studies published in scientific 
journals) can only reduce the immune response, that 
is already weak [4], [6], [11], [13], [15], [17], [18]. Giving 
chloroquine and other and other antiparasitic drugs 
justified is only if we want to achieve a reduction in the 
anti-inflammatory response. Because the majority of 
patients with such primary viral pneumonia with COVID-
19 have no problem recovering regardless of the size of 
the pathological process, it is best to leave the patient’s 
immunity to fight alone. Provide suppurative therapy, 
give Vitamin C (in high doses), and avoid intravenous 
fluids. Giving a drug without confirmed scientific proof 
that the drug is effective only, will do harm regardless of 
the doctor’s intention to do something.
Mycotic Pneumonia
Mycotic pneumonia is a possible etiological 
cause as a secondary infection in patients with 
COVID-19. Therefore, in massive bilateral pneumonias 
with a characteristic X-ray finding for COVID-19 
(peripheral nodules and milk glass findings) in which 
there are medium values of inflammatory markers 
in the blood (CRP, procalcitonin, and erythrocyte 
sedimentation rate), antimycotic replacement should be 
considered for antiparasitic and antiviral drugs that do 
not act on the COVID-19 [1], [9], [19].
Severe Pneumonia
Whether it is typical pneumonia, atypical, 
viral, mixed-type pneumonia, or mycotic pneumonia, 
it can progress to severe pneumonia. The pneumonia 
becomes severe, when breathing is over 30/min; 
diastolic pressure below 60 mmHg; low partial oxygen 
pressure in the blood (PaO2/FiO2 <250 mmHg) 
(1 mmHg = 0.133 kPa); massive pneumonia, bilateral 
or multilayered lung X-ray; desorientation; leukopenia; 
and increased urea. When a pneumonia progresses 
and becomes severe pneumonia, the patient should be 
transferred to an intensive care unit. (Note: Peripheral 
oxygen saturation of up to 90% and tachycardia up to 
110/min are not in themselves indicative of intensive 
care treatment). Switching to an intensive care unit does 
not mean immediately putting the patient on a respirator. 
Patients with COVID-19 placed in intensive care units 
should be led by a team of anesthesiologists with an 
infectious disease specialist or an anesthesiologist 
with a pulmonologist. Critical respiratory parameters 
should be peripheral oxygen saturation <90%, PaO2/
FiO2 ratio 100 or <100, and tachycardia above 110/
min. Severe acidosis itself may also be an indication for 
respiratory placement. Before setting up a respirator, 
make an operational plan, i.e., clearly set a goal of 
which parameters will be improved and for how long. 
Reduce the risks of getting ARDS from the respirator 
itself, and the risks of getting secondary pneumonia 
from a respirator [1], [6], [9], [10], [12], [20].
Conclusion
Distinguishing between typical and atypical 
bacterial pneumonia from atypical viral pneumonia 
is very important during a pandemic with COVID-19. 
Distinguishing primary viral pneumonia from secondary 
bacterial or fungal pneumonia is also important and 
will yield good results in successfully treating and 
reducing the percentage of deaths during pandemic 
with COVID-19. When we separate pneumonia with 
COVID-19, from other pneumonia, we will be able to 
analyze them much better and get much more accurate 
results. This will make it much easier and faster for 
us to come up with scientific explanations of what is 
happening to us and how to successfully oppose 
COVID-19.
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